ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Clinical trial NCT02946463 · COMPLETED
Trial details
- NCT number
- NCT02946463
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-12
- Primary completion
- 2023-02-28
- Enrollment
- 272
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.